PEGylated Exendin-4, a modified GLP-1 analog exhibits more potent cardioprotection than its unmodified parent molecule on a dose to dose basis in a murine model of myocardial infarction

Theranostics

Volumn 5, Issue 3, 2015, Pages 240-250

  Sun, Zhongchan ^a,b   Tong, Guang ^b,c   Kim, Tae Hyung ^b   Ma, Nan ^d   Niu, Gang ^b   Cao, Feng ^a,e   Chen, Xiaoyuan ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^c GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^e CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Angiogenesis; Cardioprotection; Exendin 4; Myocardial infarction; PEGylation

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CBO P 11; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; MACROGOL; PEGYLATED EXENDIN 4; PROTEIN KINASE B; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; AMINOPHYLLINE; ATROPINE; CARDIOVASCULAR AGENT; DRUG COMBINATION; GLUCAGON LIKE PEPTIDE 1; GLYCERYL TRINITRATE; MYOCARDON; PAPAVERINE; PEPTIDE; PHENOBARBITAL; VENOM;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG HALF LIFE; DRUG POTENCY; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME ACTIVITY; HEART FUNCTION; HEART INFARCTION; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HISTOLOGY; IN VIVO STUDY; MALE; MOUSE; MURINE MODEL; NONHUMAN; PROTEIN SYNTHESIS; RECEPTOR AFFINITY; SURVIVAL RATE; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CYTOCHEMISTRY; DISEASE MODEL; DRUG COMBINATION; HEART; HEART FUNCTION TEST; HEART MUSCLE; MYOCARDIAL INFARCTION; PATHOLOGY; PHYSIOLOGY; SURVIVAL; TREATMENT OUTCOME;

AMINOPHYLLINE; ANIMALS; ATROPINE; BLOTTING, WESTERN; CARDIOVASCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; GLUCAGON-LIKE PEPTIDE 1; HEART; HEART FUNCTION TESTS; HISTOCYTOCHEMISTRY; MALE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; NITROGLYCERIN; PAPAVERINE; PEPTIDES; PHENOBARBITAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VENOMS;

EID: 84924287875     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.10226     Document Type: Article

References (35)

1. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006; 3: 153-65.
2. Moberly SP, Mather KJ, Berwick ZC, Owen MK, Goodwill AG, Casalini ED, et al. Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus. Basic Res Cardiol. 2013; 108: 365.
3. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide- 1 receptor signaling modulates beta cell apoptosis. J Biol Chem. 2003; 278: 471-8.
4. Grieve DJ, Cassidy RS, Green BD. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol. 2009; 157: 1340-51.
5. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008; 117: 2340-50.
6. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009; 58: 975-83.
7. Liu FQ, Zhang XL, Gong L, Wang XP, Wang J, Hou XG, et al. Glucagon-like peptide 1 protects microvascular endothelial cells by inactivating the PARP-1/iNOS/NO pathway. Mol Cell Endocrinol. 2011; 339: 25-33.
8. Anagnostis P, Athyros VG, Adamidou F, Panagiotou A, Kita M, Karagiannis A, et al. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab. 2011; 13: 302-12.
9. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta- cells. J Biol Chem. 1993; 268: 19650-5.
10. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009; 53: 501-10.
11. Teramoto S, Miyamoto N, Yatomi K, Tanaka Y, Oishi H, Arai H, et al. Exendin- 4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2011; 31: 1696-705.
12. Bao W, Aravindhan K, Alsaid H, Chendrimada T, Szapacs M, Citerone DR, et al. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PloS one. 2011; 6: e23570.
13. Sauve M, Ban K, Momen MA, Zhou YQ, Henkelman RM, Husain M, et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes. 2010; 59: 1063-73.
14. Kim TH, Jiang HH, Lim SM, Youn YS, Choi KY, Lee S, et al. Site-specific PEGylated Exendin-4 modified with a high molecular weight trimeric PEG reduces steric hindrance and increases type 2 antidiabetic therapeutic effects. Bioconjug Chem. 2012; 23: 2214-20.
15. Zhang XX, Sun Z, Guo J, Wang Z, Wu C, Niu G, et al. Comparison of (18)F-labeled CXCR4 antagonist peptides for PET imaging of CXCR4 expression. Mol Imaging Biol. 2013; 15: 758-67.
16. Sun Z, Tong G, Ma N, Li J, Li X, Li S, et al. NDRG2: a newly identified mediator of insulin cardioprotection against myocardial ischemia-reperfusion injury. Basic Res Cardiol. 2013; 108: 341.
17. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014; 129: e28-e292.
18. Viswanathan M, Golin CE, Jones CD, Ashok M, Blalock SJ, Wines RC, et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med. 2012; 157: 785-95.
19. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 353: 487-97.
20. Peterson AM, Takiya L, Finley R. Meta-analysis of trials of interventions to improve medication adherence. Am J Health Syst Pharm. 2003; 60: 657-65.
21. Dunbar-Jacob J, Erlen JA, Schlenk EA, Ryan CM, Sereika SM, Doswell WM. Adherence in chronic disease. Annu Rev Nurs Res. 2000; 18: 48-90.
22. Zhao TC. Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protection. Cardiovasc Diabetol. 2013; 12: 90.
23. Munaf M, Pellicori P, Allgar V, Wong K. A meta-analysis of the therapeutic effects of glucagon-like Peptide-1 agonist in heart failure. Int J Pept. 2012; 249827.
24. Kang JS, Deluca PP, Lee KC. Emerging PEGylated drugs. Expert Opin Emerg Drugs. 2009; 14: 363-80.
25. Milla P, Dosio F, Cattel L. PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery. Curr Drug Metab. 2012; 13: 105-19.
26. Youn YS, Na DH, Yoo SD, Song SC, Lee KC. Carbohydrate-specifically polyethylene glycol-modified ricin A-chain with improved therapeutic potential. Int J Biochem Cell Biol. 2005; 37:1525-1533.
27. Yamamoto Y, Tsutsumi Y, Yoshioka Y, Nishibata T, Kobayashi K, Okamoto T, et al. Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat Biotechnol. 2003; 21: 546-52.
28. Moreadith RW, Collen D. Clinical development of PEGylated recombinant staphylokinase (PEG-Sak) for bolus thrombolytic treatment of patients with acute myocardial infarction. Adv Drug Deliv Rev. 2003; 55: 1337-45.
29. Rosendahl MS, Doherty DH, Smith DJ, Carlson SJ, Chlipala EA, Cox GN. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation. Bioconjug Chem. 2005; 16: 200-7.
30. Kanzler I, Tuchscheerer N, Steffens G, Simsekyilmaz S, Konschalla S, Kroh A, et al. Differential roles of angiogenic chemokines in endothelial progenitor cell-induced angiogenesis. Basic Res Cardiol. 2013; 108: 310.
31. Eapen Z, Rogers JG. Strategies to attenuate pathological remodeling in heart failure. Curr Opin Cardiol. 2009; 24: 223-9.
32. Shigeta T, Aoyama M, Bando YK, Monji A, Mitsui T, Takatsu M, et al. Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions. Circulation. 2012; 126: 1838-51.
33. Sjoholm A. Impact of glucagon-like peptide-1 on endothelial function. Diabetes Obes Metab. 2009; 11 Suppl 3: 19-25.
34. Lavu M, Gundewar S, Lefer DJ. Gene therapy for ischemic heart disease. J Mol Cell Cardiol. 2011; 50: 742-50.
35. Lehrke M, Marx N. Cardiovascular effects of incretin-based therapies. Rev Diabet Stud. 2011; 8: 382-91.